GlassScriptPhysician profile
Daniel Elbogdadi
NPI 1528186285
$21,769.34
in general payments reported to CMS, 2019-2025
23 companies · $5,215 in 2025
The $5,215 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,109 · 2020: $44.57 · 2021: $55.78 · 2022: $826 · 2023: $7,985 · 2024: $535 · 2025: $5,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $5,850 · Consulting Fee: $3,680 · Travel and Lodging: $2,567 · Food and Beverage: $1,628 · Education: $9.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $5,850.00 |
| Consulting Fee | $3,680.00 |
| Travel and Lodging | $2,567.43 |
| Food and Beverage | $1,627.58 |
| Education | $9.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $9,792.19 | 2019-2023 | Krystexxa |
| Ucb, INC. | $5,276.41 | 2019-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $3,506.12 | 2019-2024 | |
| Pacira Pharmaceuticals Incorporated | $805.05 | 2023 | Iovera |
| Amgen INC. | $662.41 | 2019-2024 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $518.93 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $404.10 | 2022-2024 | Saphnelo |
| Aurinia Pharma U.S., INC. | $172.18 | 2021-2023 | Lupkynis |
| Pfizer INC. | $114.29 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $109.86 | 2022 | |
| Lilly USA, LLC | $107.06 | 2019-2024 | Taltz, Zepbound |
| Janssen Biotech, INC. | $56.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.98 | 2019-2023 | Ofev |
| Glaxosmithkline, LLC. | $36.59 | 2019 | |
| Celgene Corporation | $31.01 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $30.90 | 2019 | |
| Boston Scientific Corporation | $22.11 | 2019 | |
| Depuy Synthes Sales INC. | $15.55 | 2019 | |
| Genentech USA, INC. | $14.15 | 2019 | |
| Sobi, INC | $13.81 | 2019 | |
| Radius Health, INC. | $13.70 | 2019 | |
| Csl Behring | $13.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Elbogdadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.